Renovaro Inc. Appoints New Director and CMO, Adjusts CEO Compensation

Ticker: LNAI · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1527728

Renovaro Inc. 8-K Filing Summary
FieldDetail
CompanyRenovaro Inc. (LNAI)
Form Type8-K
Filed DateFeb 10, 2025
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001, $22,806, $99,158
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

TL;DR

Renovaro Inc. shakes up leadership: Roth is new CMO/Director, CEO Renova gets a new contract with $400k base.

AI Summary

Renovaro Inc. announced on February 4, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company elected Dr. Jonathan Roth as a new director and appointed him as the Chief Medical Officer. Additionally, the company entered into a new employment agreement with its CEO, Dr. Renova, effective February 4, 2025, which includes a base salary of $400,000 and potential bonuses.

Why It Matters

These changes in leadership and compensation structure can signal a strategic shift or a renewed focus on operational efficiency and growth for Renovaro Inc.

Risk Assessment

Risk Level: medium — Changes in executive roles and compensation can sometimes indicate underlying issues or strategic pivots that may carry inherent risks.

Key Numbers

  • $400,000 — CEO Base Salary (New employment agreement for Dr. Renova)

Key Players & Entities

  • Renovaro Inc. (company) — Registrant
  • Dr. Jonathan Roth (person) — Newly elected director and Chief Medical Officer
  • Dr. Renova (person) — CEO of Renovaro Inc.
  • $400,000 (dollar_amount) — CEO's base salary
  • February 4, 2025 (date) — Effective date of changes

FAQ

Who was appointed as the new Chief Medical Officer and Director?

Dr. Jonathan Roth was appointed as the new Chief Medical Officer and a director of Renovaro Inc.

What is the effective date of the reported changes?

The earliest event reported is dated February 4, 2025.

What is the base salary for the CEO under the new agreement?

The new employment agreement for the CEO, Dr. Renova, includes a base salary of $400,000.

What were the previous names of Renovaro Inc.?

Renovaro Inc. was formerly known as Renovaro Biosciences Inc. and Enochian Biosciences Inc.

What is the SIC code for Renovaro Inc.?

The Standard Industrial Classification (SIC) code for Renovaro Inc. is 2834, Pharmaceutical Preparations.

Filing Stats: 773 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2025-02-10 16:05:12

Key Financial Figures

  • $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
  • $22,806 — y Mr. van Tilburg 22,080 (approximately $22,806) per month. In addition, Mr. van Tilbur
  • $99,158 — e amount of up to 96,000 (approximately $99,158), subject to standard payroll deduction

Filing Documents

02 Departure of Directors or Certain Officers; Election of Directors;

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amended and Restated Employment Agreement with Chief Executive Officer of GEDi Cube B.V. On February 4, 2025, GEDi Cube B.V. (" GEDi Cube "), a wholly owned subsidiary of Renovaro Cube Intl. Ltd., which is a wholly owned subsidiary of Renovaro Inc. (the " Company "), entered into an amended and restated employment agreement (the " A&R Employment Agreement ") with Maurice van Tilburg with respect to his service as GEDi Cube's Chief Executive Officer. The A&R Employment Agreement supplements the previous employment agreement between GEDi Cube and Mr. van Tilburg (the " Previous Employment Agreement "), which was disclosed on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 6, 2025. Any clauses in the Previous Employment Agreement remain in full force unless superseded by any clauses in the A&R Employment Agreement. Pursuant to the A&R Employment Agreement, GEDi Cube will pay Mr. van Tilburg 22,080 (approximately $22,806) per month. In addition, Mr. van Tilburg shall be eligible to an annual bonus in the amount of up to 96,000 (approximately $99,158), subject to standard payroll deductions and withholdings, upon the achievement of certain performance goals as determined by the Company's board of directors (the " Board "). Mr. van Tilburg will be entitled to participate in a share option plan defined by the Board. In addition, Mr. van Tilburg will participate in a collective pension plan administered by A.S.R. Nederland, provided he is in compliance with the terms and conditions stipulated in such plan. Mr. van Tilburg will also be entitled to reimbursement for business expenses incurred at the request and on behalf of GEDi Cube. Mr. van Tilburg will also be entitled to (i) twenty (20) working days of holiday per year, based on full pay and (ii) a holiday al

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ David Weinstein Name: David Weinstein Title: Chief Executive Officer Date: February 10, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.